3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
pembrolizumab
223
Carboplatin
219
Cisplatin
206
Paclitaxel
182
Gemcitabine
149
Docetaxel
127
Capecitabine
115
Pemetrexed
102
Dexamethasone
102
Cyclophosphamide
102
Specimen Handling
99
Magnetic Resonance Spectroscopy
97
Oxaliplatin
96
Radiotherapy
95
Doxorubicin
92
Fluorouracil
88
Bevacizumab
84
Nivolumab
74
Leucovorin
73
Rituximab
71
Vincristine
68
durvalumab
66
Lenalidomide
64
Radiation
62
Etoposide
62
atezolizumab
61
Irinotecan
61
130-nm albumin-bound paclitaxel
58
Prednisone
57
Letrozole
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hizentra
×
1 year
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled